References
- US Food and Drug Administration [homepage on the Internet]FDA approves first biosimilar product Zarxio [FDA news release]US Food and Drug Administration2016 [updated March 6, 2016] Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htmAccessed March 23, 2016
- European Medicines Agency [homepage on the Internet]Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues [report]LondonEuropean Medicines Agency Committee for Medicinal Products for Human Use (CHMP)2010 [updated May 30, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdfAccessed August 25, 2015
- Health Canada [homepage on the Internet]Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) [report]Ottawa, ON, CanadaHealth Products and Food Branch, Health Canada2010 [updated March 5, 2010]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdfAccessed August 25, 2015
- World Health Organization [homepage on the Internet]Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) [report]Geneva, SwitzerlandWorld Health Organization Expert Committee on Biological Standardization2009 [updated October 19, 2009]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdfAccessed April 7, 2015
- US Food and Drug Administration [homepage on the Internet]Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry [report]Silver Spring, MDUS Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)2015 [updated April 2015]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdfAccessed April 7, 2015
- European Medicines Agency [homepage on the Internet]Guideline on Similar Biological Medicinal Products [report]LondonEuropean Medicines Agency Committee for Medicinal Products for Human Use (CHMP)2014 [updated October 23, 2014]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdfAccessed June 5, 2015
- European Medicines Agency [homepage on the Internet]Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues Draft [report]LondonEuropean Medicines Agency Committee for Medicinal Products for Human Use (CHMP)c2013 [updated June 3, 2013]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdfAccessed August 25, 2015
- VitalEMKayJEmeryPRituximab biosimilarsExpert Opin Biol Ther20131371049106223600760
- IBM Corporation [homepage on the Internet]Column Proportions Test [user guide]Armonk, NYIBM Corporation2013 [updated 2013]. Available from: http://www-01.ibm.com/support/knowledgecenter/SSLVQG_7.0.0/com.spss.reportsforsurveys/column_proportions_test.htm?lang=enAccessed May 13, 2015
- NijstenTBergstresserPRPatient advocacy groups: let’s stick togetherJ Invest Dermatol201013071757175920548309
- Generics and Biosimilars Initiative (GaBi) Online [homepage on the Internet]Biosimilars approved in Europe [global news report]Mol, BelgiumPro Pharma Communications International2011 [updated February 27, 2015]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-EuropeAccessed April 21, 2015
- European Biopharmaceutical EnterprisesTell me the whole story: the role of product labelling in building user confidence in biosimilars in EuropeGaBi J20143416
- American Autoimmune Related Diseases Association [homepage on the Internet]Leading Autoimmune Patient Advocacy Group Survey Finds Overwhelming Majority of Patients Lack Understanding of Biosimilar Drugs [media release]New York, NYCarway Communications, Inc2015 [updated February 11, 2015]. Available from: http://www.aarda.org/wp-content/uploads/2015/02/BiosimilarsWhitePaperPressRelease.pdfAccessed March 10, 2015
- ColbertRACronsteinBNBiosimilars: the debate continuesArthritis Rheum201163102848285021702015
- KozlowskiSWoodcockJMidthunKShermanRBDeveloping the nation’s biosimilars programN Engl J Med2011365538538821812668
- SarpatwariAAvornJKesselheimASProgress and hurdles for follow-on biologicsN Engl J Med2015372252380238225946143
- Patient advocates: expanding their role in conducting successful clinical trialsJ Oncol Pract20062629829920859360
- MadsenSMHolmSDavidsenBMunkholmPSchlichtingPRiisPEthical aspects of clinical trials: the attitudes of participants in two non-cancer trialsJ Intern Med2000248646347411155139
- MadsenSMMirzaMRHolmSHilstedKLKampmannKRiisPAttitudes towards clinical research amongst participants and nonparticipantsJ Intern Med2002251215616811905591
- RompasSGossTAmanuelSDemonstrating value for biosimilars: a conceptual frameworkAm Health Drug Benefits20158312913926085901
- SocinskiMACuriglianoGJacobsIGumbinerBMacDonaldJThomasDClinical considerations for the development of biosimilars in oncologyMAbs20157228629325621390